Mereo BioPharma Group plc

Transaction in Own Shares • Aug 5, 2020

National Storage Mechanism | Additional information

RNS Number : 1507V

Mereo BioPharma Group plc

05 August 2020

Mereo BioPharma Group plc

Notification of Director Dealing

London and Redwood City, Calif., August 5, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on July 31 2020 Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 10,563 American Depositary Shares (ADSs) at a price of USD 2.85 per ADS.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

1

Details of the person discharging managerial responsibilities

a)

Name

Denise Scots-Knight

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

Price(s)	Volume(s)
USD 2.85	10,563

d)

Aggregated information:  volume, Price

e)

Date of the transaction

2020-07-31

f)

Place of the transaction

XNMS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHLZLLBBVLZBBK